Telix Pharmaceuticals Limited
TLX
$9.98
-$0.13-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.15M | -1.15M | 6.60M | 6.79M | 7.60M |
| Total Depreciation and Amortization | 4.79M | 4.79M | 1.41M | 1.45M | 1.59M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.23M | 5.23M | 14.22M | 14.62M | 10.49M |
| Change in Net Operating Assets | -- | -- | -20.94M | -21.53M | -- |
| Cash from Operations | 8.87M | 8.87M | 1.29M | 1.32M | 19.68M |
| Capital Expenditure | -3.33M | -3.33M | -3.14M | -3.23M | -1.48M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -114.84M | -114.84M | -3.73M | -3.84M | -15.57M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.26M | -11.26M | -22.23M | -22.86M | -7.43M |
| Cash from Investing | -129.43M | -129.43M | -29.11M | -29.93M | -24.48M |
| Total Debt Issued | -- | -- | 326.62M | 326.62M | 990.40K |
| Total Debt Repaid | -1.80M | -1.80M | -974.50K | -974.50K | -787.00K |
| Issuance of Common Stock | 338.00K | 338.00K | 182.50K | 182.50K | 311.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -7.44M | -7.44M | 1.88M |
| Cash from Financing | -1.46M | -1.46M | 207.47M | 213.33M | 2.40M |
| Foreign Exchange rate Adjustments | 5.59M | 5.59M | 13.07M | 13.44M | -2.53M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.42M | -116.42M | 192.72M | 198.17M | -4.93M |